ARDELYX, INC. (ARDX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0396971071
ARDELYX, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 407.32 m USD |
| Gross profit | 367.78 m USD |
| Operating income | -40.98 m USD |
| EBIT | -40.53 m USD |
| Net income | -61.60 m USD |
| Diluted EPS – continuing operations | -0.26 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ARDELYX, INC.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
More stocks
- Guangzhou Haoyang Electronic Co Ltd (300833.SZ)
- Suzhou Wanxiang Technology Co. Ltd. (301180.SZ)
- SWS Hemodialysis Care Co. Ltd. A (688410.SS)
- QuidelOrtho Corp (QDEL)
- NPK International Inc. (NPKI)
- World Financial Holding Group (WFHG)
- Aspen Group Ltd (APZ.AX)
- Bain Capital Specialty Finance, Inc. (BCSF)
- Astroscale Holdings Inc (186A.T)
- Chatham Lodging Trust (CLDT)
- Xinlei Compressor Co. Ltd. A (301317.SZ)
- Beijing Asiacom Information Technology Co.Ltd (301085.SZ)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.